Respiratory Biologics Market Report 2026

The respiratory biologics market size has grown rapidly in recent years. It will grow from $7.41 billion in 2025 to $8.61 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to limitations of conventional inhalers, rising severe asthma cases, biologic therapy approvals, improved immunology research, specialty clinic expansion.

The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $15.66 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to precision respiratory medicine growth, expansion of biologics pipelines, rising healthcare spending, improved reimbursement policies, unmet needs in severe respiratory disease. Major trends in the forecast period include rising adoption of targeted biologic therapies, expansion of severe asthma treatments, growth of biomarker-based patient selection, increasing use of injectable respiratory drugs, shift toward long-acting biologic agents.

The surge in air pollution is projected to boost the respiratory biologics market in the years ahead. Air pollution involves harmful substances like gases, particulate matter, and biological agents in the Earth's atmosphere, adversely affecting human health and the environment. It is escalating due to expanding industrialization and urbanization, which increase pollutant emissions from factories, vehicles, and construction. Respiratory biologics address the health impacts of air pollution through precise therapies that alleviate inflammation and enhance lung function for those exposed to airborne contaminants. For instance, in January 2025, the Environmental Protection Agency - a US government agency - reported that the United States emitted more than 66 million tons of pollutants into the atmosphere in 2023. Thus, escalating air pollution is fueling expansion in the respiratory biologics market.

Major companies in the respiratory biologics market are prioritizing the development of cutting-edge biologic therapies, including targeted immune treatments for chronic respiratory conditions, to deliver precise interventions that curb inflammation and enhance lung performance. Targeted immune therapies for chronic respiratory diseases work by modulating the body's immune response to alleviate swelling and breathing difficulties in persistent lung disorders. For example, in September 2024, Sanofi S.A., a pharmaceutical firm headquartered in France, revealed that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) as an additional maintenance treatment for adults suffering from uncontrolled chronic obstructive pulmonary disease (COPD) with an eosinophilic profile. This approval represented a key achievement, positioning Dupixent as the inaugural biologic drug cleared in the US for this particular subset of COPD patients.

In February 2024, GlaxoSmithKline plc, a pharmaceutical firm headquartered in the UK, purchased Aiolos Bio for an undisclosed sum. Through this deal, GSK seeks to bolster its respiratory and immunology lineup by gaining access to Aiolos Bio’s cutting-edge therapies targeting inflammatory and immune-mediated conditions. Aiolos Bio, based in the US, specializes in creating biologic treatments for respiratory and inflammatory disorders.

Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the respiratory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the respiratory biologics market by increasing the cost of imported biologic drug substances, cell culture materials, and cold-chain packaging components. These impacts have been most pronounced in monoclonal antibody therapies, particularly in north america and europe where biologic manufacturing inputs are globally sourced. Asia-pacific producers have faced cold-chain logistics cost pressures. However, tariffs have encouraged regional biologics manufacturing and local fill-finish capacity expansion, supporting supply continuity.

The respiratory biologics market research report is one of a series of new reports that provides respiratory biologics market statistics, including respiratory biologics industry global market size, regional shares, competitors with a respiratory biologics market share, detailed respiratory biologics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory biologics industry. This respiratory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory biologics are precision therapies from living organisms that target specific immune molecules like interleukins (IL-4, IL-5, IL-13) or IgE to curb inflammation and boost breathing in chronic respiratory diseases; they're typically prescribed for severe, uncontrolled cases unresponsive to standard treatments such as inhaled corticosteroids and bronchodilators.

Respiratory biologics primarily target diseases like asthma, chronic rhinosinusitis, and hypereosinophilic syndrome. Asthma represents a chronic inflammatory condition of the airways, leading to breathing difficulties, wheezing, and coughing from narrowed airways and heightened responsiveness. Available administration routes encompass intravenous and subcutaneous methods, with distribution through channels including hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.

The respiratory biologics market consists of sales of monoclonal antibodies (mAbs), interleukin inhibitors, and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.